March 16, 2017
Launch of the DAMS clinical study
Ad Scientiam launches its own clinical validation study with more than 200 participants in 10 neurology centers specializing in the management of multiple sclerosis.
Ad Scientiam is devoting its efforts and resources to an innovative medical-digital research project in neurology: "DAMS, Digital Assessment in Multiple Sclerosis."
This project brings together teams from 10 French hospitals specializing in neurology and particularly in MS.
The main objective of this study is to demonstrate the validity and robustness of a new composite score for assessing multiple sclerosis, measured through exercises performed on a smartphone.
The first step is to evaluate the benefit of the DAMS (Digital Assessment in Multiple Sclerosis) app in 200 participants.
This multicenter study is the first step of a program that aims to provide assessment scales for chronic diseases.
"Ad Scientiam is committed to developing innovative applications for monitoring and assessing patients in real life. The fact that our activities are based at the Brain and Spine Institute (ICM), at the heart of the largest hospital in Europe, facilitates collaboration with the leading French academic teams. DAMS is a real opportunity to identify new monitoring parameters for patients," explains Séverine Bieuvelet, Head of Clinical Operations at Ad Scientiam.
About multiple sclerosis
Multiple sclerosis (MS) currently affects between 70,000 and 90,000 patients in France, with a probable annual incidence of 4 to 6 per 100,000 inhabitants. It is a chronic disease that affects the myelin of the central nervous system through a mechanism that is still poorly understood.
With onset at an average age of 30 (20-40 years) and a female predominance (sex ratio of 1.7:1), it is the leading non-traumatic cause of severe acquired disability in young adults.
The impact of disability and handicap on daily family and professional life is often major.